Latest XVIVO News & Updates

See the latest news and media coverage for XVIVO. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
XVIVO

Organ perfusion technologies provider

xvivogroup.com
Headquarters
Mölndal, Sweden
Founded year
1998
Company type
Public company
Number of employees
50–300

Last updated

Latest news about XVIVO

In short: XVIVO reported strong Q1 2026 financial growth and achieved positive clinical trial outcomes for its heart and liver preservation technologies.

Company announcements

  • XVIVO

    XVIVO’s Liver Assist boosts liver transplants 70%

    Sir Charles Gairdner Hospital in Australia adopts combined perfusion technology, increasing transplants and reducing waitlist mortality since 2025.

  • XVIVO

    XVIVO holds Annual General Meeting

    Resolutions include adopting 2025 financials, no dividend, board re-elections, new incentive program, and share issue authorizations.

  • XVIVO

    XVIVO reports Q1 2026 financial results

    Net sales reached SEK 241 million, up 10%. Organic growth was 23% in local currencies. EBIT was SEK 31.9 million. Positive cash flow achieved.

  • XVIVO

    XVIVO presents encouraging HOPE trial results

    The trial met its primary endpoint with 98% 30-day survival, low graft dysfunction, using XVIVO Heart Assist Transport for DCD hearts. Experts highlight feasibility and logistical benefits.

Unlock all announcements with a

Media coverage

  • Morningstar

    Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

    The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Company") held today on...

  • Morningstar

    Interim Report January - March 2026

    GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding...

  • Dagens industri

    Xvivo study reached primary endpoint - "very promising"

    Close LIVE: Stock market morning April 23. The transplantation company Xvivo's first clinical study for direct management of DCD hearts using hypothermic oxygenated perfusion, Hope, achieved its predefined...

  • Morningstar

    XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion...

    GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were...

Unlock all articles with a

Never miss news about XVIVO

Track XVIVO and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.